The Value of PET/CT Imaging in Alzheimer’s Disease Patients with Different Levels of Estradiol

doi:10.7538/tws.2017.youxian.035

Abstract

Abstract:

The expressions of aplipoprotein E (ApoE), tumor necrosis factor-α (TNF-α) in Alzheimer’s disease (AD) patients with different levels of estrogen were investigated to evaluate the diagnosis of combined PET/CT imaging (¹¹C-PIB and ¹⁸F-FDG) on AD. A total of 75 female AD patients were divided into low level of estradiol group (E₂<16.2 pmol/L, n=36) and normal level of estradiol group (16.2 pmol/L≤E₂<65.7 pmol/L, n=39) according to their estradiol levels. All the patients underwent PET/CT imaging (¹¹C-PIB and ¹⁸F-FDG). The sensitivity of PET/CT imaging, the standard uptake value radio, the expression rates of subtype ApoE (ε2, ε3, ε4) , and the expression levels of TNF-α were detected. The relationship between E₂ and the expression rates of ApoE, the levels of TNF-α and SUVR were analyzed by Pearson analysis. In the low level of E₂ group, the sensitivity of PET/CT for ¹¹C-PIB alone, ¹¹C-PIB combined with ¹⁸F-FDG was higher than in normal E₂ group (χ²=4.869,P=0.027; χ²=3.636, P=0.047）; while the sensitivity of ¹⁸F-FDG PET/CT imagings on brain between the two groups had no significant difference (χ²=2.007, P=0.157). The expression level of E₂ with SUVR and the expression level of TNF-α in two groups of AD patients had the negative correlations (r=-0.363, P=0.001; r=-0.248,P=0.032). The expression rate of ApoE ε4 allelic genes of AD patients was higher than that of ε2 and ε3 allelic genes, and there was higher expression rates of ApoE in AD patients with the low E₂ group (Z=-2.228,P=0.026）. ¹¹C-PIB and ¹⁸F-FDG PET/CT had high value of diagnosis in AD patients.

Key words: Alzheimer’s disease, estradiol, apolipoprotein E, tumor necrosis factor-α

摘要：

通过研究不同雌二醇（estradiol, E₂）水平阿尔茨海默病（AD）患者血清中肿瘤坏死因子-α（Tumor necrosis factor-α, TNF-α）及载脂蛋白E（ApoE）的表达，探讨¹¹C-PIB、¹⁸F-FDG PET/CT联合显像对AD的诊断价值。分析绝经后女性AD患者75例，依据雌激素水平分为低E₂组（E₂<16.2 pmol/L, n=36）、正常E₂组（16.2 pmol/L≤E₂<65.7 pmol/L, n=39）。检测两组患者血清中ApoE等位基因（ε2、ε3、ε4）表达率、TNF-α表达水平以及PET/CT脑显像标准化摄取比值（standard uptake radio, SUVR）。研究发现，在不同E₂组AD患者中，低E₂组¹⁸F-FDG联合¹¹C-PIB及单独¹¹C-PIB脑显像诊断AD的灵敏度均较正常E₂组高，差异显著（χ²=4.869,P=0.027;χ²=3.636, P=0.047）；AD患者E₂水平与SUVR及TNF-α表达水平均呈负相关关系（r=-0.363，P=0.001；r=-0.248，P=0.032），而SUVR及TNF-α表达水平之间无明显相关性（r=0.161，P=0.168）；低E₂水平AD患者组ApoE等位基因表达率高，差异显著（Z=-2.228，P=0.026）。结果表明，¹¹C-PIB和¹⁸F-FDG联合显像对AD患者具有较高的诊断价值。

关键词: 阿尔茨海默病, 雌二醇, 载脂蛋白E, 肿瘤坏死因子-&alpha

LU Guo-xiu;ZHANG Guo-xu;HAO Shan-hu;GUO Jia;ZHANG Wen-wen;WANG Zhi-guo;ZHANG Jing-hua. The Value of PET/CT Imaging in Alzheimer’s Disease Patients with Different Levels of Estradiol[J]. Journal of Isotopes, 2017, 30(4): 276-282.

陆国秀;张国旭;郝珊瑚;郭佳;张文文;王治国;张景华. PET/CT联合显像在雌激素与阿尔茨海默病相关性研究中的价值[J]. 同位素, 2017, 30(4): 276-282.

References

［1］Gillies G E,McArthur S. Estrogen actions in the brain and the basis for differential action in men and women：a case for sex-specific medicines［J］. Pharmacol Rev, 2010, 62(2): 155-198.
［2］Tang M X, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease［J］. Lancet, 1996, 348: 429-432.
［3］熊元元,李有秋,彭耀金. 阿尔茨海默病与雌激素和褪黑素的相关性研究进展［J］. 现代生物医学进展,2011,11(12):2376-2380.Xiong Yuanyuan, Li Youqiu,Peng Yaojin.Correlation of Alzheimer’s disease to estrogen and melatonin［J］.Progressin Modern Biomedicine, 2011, 11(12): 2376-2380(in Chinese).
［4］邢恩鸿，建丽，王爱霞,等. 肿瘤坏死因子-α、白细胞介素-1β在淀粉样蛋白致阿尔茨海默病大鼠神经元损伤中的作用［J］. 中国老年学杂志,2014,34(20):5802-5804.Xing Enhong, Jian Li, Wang Aixia, et al. The roles of TNF-α、IL-1β in Aβ protein Alzheimer disease on Neuronal damage in rat［J］. Chinese Journal of Gerontology, 2014, 34(20): 5802-5804(in Chinese).
［5］De Marinis E, Ascenzi P, Pellegrini M, et al. 17β-estradiol-a new modulator of neuroglobin levels in neurons:role in neuroprotection against H₂O₂ Induced toxicity［J］. Neurosignals, 2010, 18(4): 223-235.
［6］Chen C S, Pei O Y, Yeh Y C, et al. Apolipopmtein E polymorphism and behavioral and psychological symptoms of dementia in patients with Alzheimer disease［J］. Alzheimer Dis Assoc Disord, 2012, 26(2): 135-139.
［7］Veryard L, Jones E, Weaving G, et al. Pro-inflammatory cytokines IL-1 β and TNF-α are not associated with plasma homocysteine concentration in Alzheimer’s disease［J］. Curr Alzheimer Res, 2013, 10(2): 174-179.
［8］Duhois B, FeIdman H H, Jacova C, et al. Advancing research diagnostic criteria for AIzheimer’s disease: The IWG2 criteria［J］. Lancet Neurol, 2014, 13(6): 614-629.
［9］尚琨,卢洁. β淀粉样蛋白正电子发射断层成像显像在阿尔茨海默病早期诊断中的研究进展［J］. 中华老年心脑血管病杂志,2016,18（8）:889-890.
［10］Kantarci K, Lowe V, Przybelski S A, et al. APOE modifies the association between Aβ and cognition with cognitively normal older adults［J］. Neurology, 2012, 78(4): 232-240.
［11］Mathis C A, Wang Y, Holt D P, et al. Synthesis and evaluation of ¹¹C-labeled 6-substituted 2-arylbenzothiazolesas amyloid imaging agents［J］. J Med Chem, 2003, 46(13): 2740-2754.
［12］Hixson J E, Vernier D T. Restriction isotyping of human apolipo protein E by gene amplification and cleavage with HhaI［J］. J Lipid Res,1990, 31(3): 545-548.
［13］Shea Y F, Joyce H A, Lee S C, et al. Impact of 18-FDG PET and ¹¹C-PIB PET brain imaging on the diagnosis of Alzheimer’s disease and other dementias in a regional memory clinic in Hong Kong［J］. Hong Kong Med J, 2016, 22(4): 327-333.
［14］Matousek S B, Ghosh S, Shaftel S S, et al. Chronic IL-1 beta-mediated neuroinflammation mitigates amyloid pathology in a mouse model of Alzheimer’s disease without inducing overt neurodegeneration［J］. J Neuroimmune Pharmacol, 2012, 7(1): 156-164.
［15］Takeuchi H, Jin S, Wang J, et al. Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner［J］. J Biol Chem, 2006, 281( 30): 21362-21368.
［16］Brinton R D. The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications［J］. Trends Neuro, 2008, 31(10): 529-537.
［17］Pike C J, Carroll J C, Rosario E R, et al. Protective actions of sex steroid hormones in Alzheimer’s disease［J］. Front Neuroendocrinol, 2009, 30(2): 239-258.
［18］Jayaraman A,Carroll J C,Morgan T E, et al. 17 beta-estradiol and progesterone regulate expression of betaamyloid clearance factors in primary neuron cultures and female rat brain［J］. Endocrinology, 2012, 153(11): 5467-5479.
［19］George S, Petit G H, Gouras G K, et al. Nonsteroidal selective androgen receptor modulators and selective estrogen receptor β-agonists moderate cognitive deficitsand amyloid-β levels in a mouse model of Alzheimer’s disease［J］. ACS Chem Neurosci, 2013, 4(12): 1537-1548.
［20］Merlo S, Sortino M A. Estrogen activates matrix metalloproteinases-2 and 9 to increase beta amyloid degradation［J］. Mol Cell Neurosci, 2012, 49(4): 423-429.
［21］Lee M J,Lee J H,Rubinsztein D C. Tau degradation:the ubiquitin-proteasome system versus the autophagy lysosome system［J］. Prog Neurobiol, 2013, 105(6): 49-59.
［22］Liraz O, Boehm-Cagan A, Michaelson D M. ApoE4 induces a beta 42, tau, and neural pathology in the hippocampus of young targeted replacement ApoE4 mice［J］. J Mol Neurodegener, 2013, 8: 16.
［23］Crescenzi R, De Brosse C, Nanga R P, et al. In vivo measurement of glutamate loss is associated with synapse loss in a mouse model of tauopathy［J］. Neuroimage, 2014, 101(1): 185-192.
［24］Burbaeva G S,Boksha I S, Tereshkina E B. et al. A role of glutamate decarboxy-lase in Alzheimer’s disease［J］. Zh Nevrol Psikhiatr Im S S Korsakova, 2014, 114(4): 68-72.
［25］Ribeiro F M, Devries R A, Hamilton A, et al. Metabotropic glutamate receptor 5 knockout promotes motor and biochemical alterations in a mouse model of Huntington’s disease［J］. Hum Mol Genet, 2014, 23(8): 2030-2042.
［26］Riise J, Plath N, Pakkenberg B, et al. Aberrant Wnt signaling pathway in medial temporal lobe structures of Alzheimer ’s disease［J］. J Neural Transm (Vienna), 2015, 122(9): 1303-1318.
［27］Peng Y, Jiang B, Wu H, et al. Effects of genistein on neuronal apoptosis,and expression of Bcl₂ and Bax proteins in the hippocampus of Ovariectomizedrats［J］. N Neural Regen Res, 2012, 7(36): 2874-2881.
［28］Spencer J P. The interactions of flavonoids within neuronal signalling pathways［J］. Genes & Nutrition, Genes Nutr, 2007, 2(3): 257-73.
［29］Barthel H, Gertz H J, Dresel S, et al. Cerebral amyloid-β PET with florbetaben (¹⁸F) in patients with Alzheimer’s disease and healthy controls:a multicentre phase 2 diagnostic stufy［J］. Lancet Neurol, 2011, 10(5): 425-435.
［30］Castellano J M, Kim J, Stewart F R, et al. Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance［J］. Sci Transl Med, 2011, 3(89): 89-57.
［31］Han X, Aenlle K K, Bean L A, et al. Role of estrogen receptor α and βin preserving hippocampal function during aging［J］. J Neurosci, 2013, 33(6): 2671-2683.

[1]	LI Zhongyong;CUI Haiping. Research Progress of Aβ Targeting PET Imaging Agents for Alzheimer’s Disease [J]. Journal of Isotopes, 2020, 33(1): 27-37.
[2]	LIU Yinli;LI Zhongyong. Preparation of ¹⁸F-Labeled Styryl Nitrogenous Heterocycles [J]. Journal of Isotopes, 2018, 31(1): 33-41.
[3]	ZHANG Zheng-wei;ZHU Jian-hua;YAO Zhi-wen;GUAN Yi-hui;HUA Feng-chun. Modified Auto-synthesis and Clinical Trial of the ¹¹C-PIB as a Potential β-amyloid Imaging Agent [J]. Journal of Isotopes, 2017, 30(1): 23-28.
[4]	PENG Cheng;CUI Meng-chao;LIANG Zhi-gang;LIU Ting-ting;ZHANG Xiao-yang. Synthesis and Evaluation of ¹²⁵I Labeled Chalcone Derivatives Containing Bithiophene Moiety as Potential Aβ Probes [J]. Journal of Isotopes, 2015, 28(4): 253-258.
[5]	SUN Chuan-jin;ZHU Hong;FANG Ke-yuan. Preparation of 16α-［¹⁸F］fluoro-17β-fluoroestradiol on Domestic Synthesis Module [J]. Journal of Isotopes, 2012, 25(3): 155-159.